medius KLINIKEN gGmbH

At medius KLINIKEN gGmbH, researchers are advancing care for gastrointestinal malignancies by evaluating new treatment sequences and personalized approaches that aim to improve survival and preserve organ function.

• Adjuvant therapy guided by circulating tumor DNA in stage II colon cancer to enhance disease‑free survival.
• Organ‑preservation strategies for intermediate and high‑risk rectal cancer using short‑course radiotherapy and consolidation chemotherapy.
• Comparison of pre‑operative chemotherapy versus risk‑adapted adjuvant therapy in locally advanced rectal cancer.
• Evaluation of neuroprotective adjuncts to reduce chemotherapy‑induced polyneuropathy in patients receiving oncologic treatment.

These initiatives reflect the site’s commitment to integrating innovative protocols into routine practice for patients with colorectal and gastric diseases.

The oncology program at medius KLINIKEN focuses on testing novel drug combinations for advanced and metastatic tumors, seeking to extend overall survival and improve response rates.

• Second‑line comparison of ramucirumab + irinotecan versus ramucirumab + paclitaxel in metastatic gastric and gastro‑esophageal adenocarcinoma.
• Combination of D,L‑methadone with mFOLFOX6 for chemorefractory colorectal cancer to assess disease‑control outcomes.
• Phase‑III evaluation of pre‑operative systemic therapy in advanced colon cancer to determine impact on surgical success and long‑term survival.
• Investigation of targeted therapies in metastatic colorectal carcinoma to identify biomarkers of response.

By conducting these studies, the center aims to bring effective, personalized cancer treatments to patients across Europe.

Research at the site also addresses neurotoxic side effects of cancer therapy, with trials designed to prevent and mitigate peripheral nerve damage.

• Placebo‑controlled trial of Aconite Pain Oil to lower the incidence of grade II or higher chemotherapy‑induced polyneuropathy.
• Quality‑of‑life assessment for patients receiving neuroprotective interventions during neurotoxic chemotherapy.
• Exploration of integrative strategies to preserve nerve function while maintaining oncologic efficacy.

These efforts underscore the institution’s dedication to safeguarding neurological health alongside cancer treatment.